Single ventricle is a rare yet complicated heart condition, with a birth incidence of roughly 4–8 per 10,000, it accounts for 7.7% of congenital heart disease identified in children. Most patients will have neonatal cyanosis when they first arrive, but prenatal ultrasonography is now able to identify more of them. The single ventricle heart disease pipeline analysis by Expert Market Research focuses on various treatment options for this disease. Recent developments include small molecule and biologics. Increasing research, improved diagnostics, and innovative treatments are expected to fuel the growth of single ventricle heart disease drug candidates in the coming years.
Major companies involved in the single ventricle heart disease pipeline analysis include Regeneron Pharmaceuticals, Mezzion Pharma Co. Ltd, Merck Sharp & Dohme LLC and others.
Leading drugs currently in the pipeline include Vericiguat, Udenafil, and REGN5381, among others.
Advancements in novel antiviral therapies and immune-modulating agents are driving pipeline growth. Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Single Ventricle Heart Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into single ventricle heart disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Single Ventricle Heart Disease therapeutics. The single ventricle heart disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The single ventricle heart disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with single ventricle heart disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to single ventricle heart disease.
Single ventricle heart disease (SVHD) is a rare congenital heart condition where one of the heart’s two pumping chambers (ventricles) is underdeveloped or absent. This severely limits the heart’s ability to circulate blood efficiently, often requiring infants to undergo a series of surgeries to reroute blood flow. SVHD typically includes conditions like hypoplastic left heart syndrome or tricuspid atresia, and is associated with significant long-term health challenges, including exercise intolerance, heart failure, and arrhythmias.
SVHD is managed through staged surgical interventions, namely, Norwood, Glenn, and Fontan procedures. These procedures create alternative circulatory pathways. Post-surgery, ongoing treatment includes medications to support heart function, manage symptoms, and improve quality of life. Emerging pharmacologic therapies aim to enhance exercise capacity, cardiac output, and long-term outcomes in patients living with Fontan physiology. For example, in 2023, Mezzion Pharma Co. Ltd. submitted a New Drug Application (NDA) to the US FDA for Udenafil, a PDE5 inhibitor, for adolescents with Fontan physiology. This makes Udenafil a leading investigational therapy targeting long-term complications of single ventricle heart disease.
Single ventricles are very uncommon. 5 kids out of 10,000 are born with only one ventricle. The number of people with single ventricle heart disease who have Fontan circulation has increased to about 700,000 worldwide, with about half of them being older than 18, thanks to notable improvements in survival over the previous 40 years.
This section of the report covers the analysis of single ventricle heart disease drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total single ventricle heart disease clinical trials.
In the single ventricle heart disease pipeline, most candidates are in Phase III with 40% of the projects, followed by 20% in Phase I and 20% in Phase IV. Additionally, 20% are in Early Phase I, demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
The drug molecule categories covered under the single ventricle heart disease pipeline analysis include small molecules and biologics. The single ventricle heart disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for single ventricle heart disease.
Particularly for individuals with Fontan physiology, soluble guanylate cyclase (sGC) stimulators are becoming new therapeutic medicines in the pipeline for single ventricle heart disease (SVHD). The nitric oxide (NO)-sGC-cyclic GMP (cGMP) signaling cascade, which is frequently dysregulated in SVHD, is enhanced by these tiny compounds, such as vericiguat. These drugs increase cardiac efficiency, decrease ventricular afterload, and enhance systemic and pulmonary vasodilation by directly activating sGC regardless of no availability. By addressing important physiological deficiencies that are not being addressed by current surgical or supportive care approaches, their dual action shows promise in enhancing exercise capacity, oxygen delivery, and long-term heart function in post-Fontan patients.
The EMR report for the single ventricle heart disease pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in single ventricle heart disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase II, phase III, phase IV, and emerging drugs for single ventricle heart disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of single ventricle heart disease drug candidates.
The experimental small molecule Vericiguat is under development by Merck Sharp & Dohme LLC to treat single ventricle heart disease. It enhances the nitric oxide (NO)-sGC-cyclic GMP (cGMP) signaling pathway, which is essential for cardiovascular control, by acting as a soluble guanylate cyclase (sGC) stimulator. Vericiguat stimulates sGC directly and raises intracellular cGMP levels, which improves tissue perfusion, myocardial function, and vasodilation. The medication's effectiveness, safety, and effect on cardiac function in patients with single ventricle physiology, a complicated congenital heart abnormality that frequently results in heart failure are being assessed clinically. This finding offers a possible expansion into juvenile and congenital cardiology settings, building on Vericiguat's previous approval for heart failure with reduced ejection fraction (HFrEF).
Mezzion Pharma Co. Ltd. created the phosphodiesterase type 5 (PDE5) inhibitor Udenafil, which is being tested for the treatment of single ventricle heart disease, especially in young adults and adolescents who have had the Fontan operation. By preventing the breakdown of cyclic guanosine monophosphate (cGMP), udenafil improves the nitric oxide–cGMP pathway, resulting in vasodilation, decreased pulmonary vascular resistance, and increased cardiac output. Exercise intolerance and increasing heart failure are two long-term issues linked to Fontan physiology that the medication attempts to treat. The Fontan Udenafil Exercise Longitudinal (FUEL) experiment examined udenafil and showed promise in enhancing heart function and exercise capacity. Confirming its effectiveness, safety, and quality-of-life enhancements in this high-risk population with congenital cardiac disease is the goal of the current development effort.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The single ventricle heart disease drug pipeline insight report provides a strategic overview of the latest and future landscape of treatments for single ventricle heart disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into single ventricle heart disease collaborations, regulatory environments, and potential growth opportunities.
Global Heart Health Supplements Market
Global Heart Murmur Devices Market
Global Transcatheter Heart Valve Replacement and Repair Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share